Atreca to Participate at Cowen’s 43rd Annual Health Care Conference

Rhea-AI Summary

Atreca, Inc. (NASDAQ: BCEL), a clinical-stage biotechnology firm, announced that CEO John A. Orwin will partake in a panel discussing novel oncology targets at Cowen’s 43rd Annual Health Care Conference, scheduled for March 7, 2023, from 9:10 to 10:20 AM EST.

The discussion will be accessible via a live webcast on the company's website, with an archived replay available for 30 days post-conference. Atreca specializes in developing innovative antibody-based immunotherapeutics through its unique discovery platform, aiming to advance its lead product candidate, ATRC-101, currently in a Phase 1b study for multiple solid tumor cancers.

SAN CARLOS, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that John A. Orwin, President and Chief Executive Officer, will be participating in a panel discussion focused on novel oncology targets at Cowen’s 43^rd Annual Health Care Conference on March 7, 2023, from 9:10 to 10:20 AM EST.

A live webcast of Atreca’s panel can be accessed through the Events & Presentations section of the Company's website at http://ir.atreca.com. An archived replay of the panel will be available on the Company's website for 30 days following the end of the conference.

About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101, our pipeline of lead-stage oncology programs, and MAM01/ATRC-501, a clinical candidate licensed to the Bill & Melinda Gates Medical Research Institute for the prevention of malaria. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

Forward-Looking Statements
This release contains statements regarding matters that are not historical facts that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our strategy and future plans, including statements regarding the development of ATRC-101, ATRC-501, and our preclinical and clinical plans and the timing thereof. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

Contacts

Atreca, Inc.
Herb Cross
Chief Financial Officer
info@atreca.com

Investors:
Alex Gray, 650-779-9251
agray@atreca.com

Media:
Julia Fuller, 858-692-2001
Julia@fordhutmanmedia.com

 

FAQ

What is the date and time for Atreca's panel discussion at the Cowen Conference?

Atreca's panel discussion will take place on March 7, 2023, from 9:10 to 10:20 AM EST.

Where can I access the live webcast of Atreca's panel?

The live webcast of Atreca's panel can be accessed through the Events & Presentations section on their website.

What is the focus of Atreca's panel discussion at the conference?

The panel discussion will focus on novel oncology targets.

What is ATRC-101 and its current status?

ATRC-101 is Atreca's lead product candidate currently being evaluated in a Phase 1b study for multiple solid tumor cancers.

How long will the archived replay of Atreca's panel be available?

The archived replay of the panel will be available for 30 days following the conference.